Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion

Angelini Pharma, an Italian pharmaceutical company, announced its acquisition of Catalyst Pharmaceuticals for $4.1 billion. Catalyst Pharmaceuticals specializes in developing and marketing drugs for rare diseases.

The acquisition, which was made public on Thursday, May 7, 2026, will give Angelini Pharma control of Catalyst’s portfolio of rare disease treatments. The deal expands Angelini Pharma’s reach into the rare disease market.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI